Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Standard BioTools Temettü

Temettü kriter kontrolleri 0/6

Standard BioTools şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	0.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.44
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Sep 14

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 05

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Jul 26

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LAB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LAB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Standard BioTools Piyasaya Karşı Temettü Getirisi

LAB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LAB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Life Sciences)	0.3%
Analist tahmini (LAB) (3 yıla kadar)	n/a

Önemli Temettü: LAB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LAB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LAB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LAB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Standard BioTools Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Consensus revenue estimates decrease by 15%

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

No longer forecast to breakeven

Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Standard BioTools Inc. Announces Chief Financial Officer Changes

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Forecast to breakeven in 2026

High number of new and inexperienced directors

Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024

Standard BioTools Inc., Annual General Meeting, Jun 27, 2024

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024

Standard BioTools Inc. Announces Operational Restructuring Plan

Now 21% undervalued

Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Consensus EPS estimates upgraded to US$0.43 loss

Chief Strategy Officer notifies of intention to sell stock

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Forecast to breakeven in 2026

Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024

New major risk - Financial position

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

New major risk - Revenue and earnings growth

Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023

High number of new directors

Senior VP & CFO recently bought US$194k worth of stock

Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer

First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022)

Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors

Chief Financial Officer exercised options and sold US$58k worth of stock

Standard BioTools Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021)

Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023

Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer

Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)

Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021)

Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022

Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022

Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary

Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations

Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Standard BioTools Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$6.00

Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022

Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

Independent Director exercised options to buy US$80k worth of stock.

Fluidigm Corporation Announces Board Changes

Fluidigm Corporation Announces Management Changes

Price target decreased to US$6.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Fluidigm Corporation: Investment Opportunity

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

President exercised options and sold US$51k worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020)

Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry Technologies

President exercised options and sold US$74k worth of stock

Price target increased to US$11.00